New Frontier Possibility for Preventing Ovarian Cancer

New Frontier Possibility for Preventing Ovarian Cancer

Cancer-News

3 weeks
10 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Curtis McCloskey, PhD of @ottawahospital provides insight on a possible new frontier for preventing ovarian cancer.

____________

A laboratory study published in Clinical Cancer Research provides a new perspective on how ovarian cancer is developed and suggests how it can be avoided.

The research is the first to demonstrate that with age occurs the normal ovarian stiffening called fibrosis. It also indicates that this cycle may be prevented by the diabetes medication metformin.

"Fibrosis happens when body tissues are repeatedly injured and inflamed, leaving behind hard collagen fibers that pile up over time, like a scar on the skin," said Dr. Curtis McCloskey, the lead author, "Cancer cells tend to like growing in these fibrotic tissues.

Dr. McCloskey performed the research while he was a PhD student in Dr. Barbara Vanderhyden's lab at The Ottawa Hospital and the University of Ottawa. He is now a postdoctoral fellow at the Princess Margaret Cancer Centre.

Ovarian cancer is the fifth most common cancer in women, with a 5-year survival rate of 45 percent among the worst. People with a family history of ovarian cancer or a BRCA gene mutation are the most susceptible. There is no accurate early cancer screening study. Birth control pills that reduce the risk of ovarian cancer by half or remove ovaries and fallopian pipes are the only options for prevention.

The team found that ovarian fibrosis is a common part of aging, usually after menopause. Dr. McCloskey was shocked during his research to find an ovary by a 69-year-old woman without fibrosis. Medical records revealed that she took metformin, a type 2 diabetes drug. A Taiwanese study previously showed an 82% decrease in ovarian cancer levels in patients with metformin Type 2 diabetes.

The group conducted a series of trials to explore the relations between ovarian fibrosis, aging and metformin.

Read here: https://www.oncologytube.com/video/-wild-idea-opens-possible-new-boundaries-to-ovarian-cancer-prevention

Up Next Autoplay
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
19 Views
SeattleCCA 4 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
11 Views
Cancer-News 4 days
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
7 Views
MD Anderson 4 days
KY1044 Targets ICOS @kymabltd @rcasainson
KY1044 Targets ICOS @kymabltd @rcasainson
Category: Other
3 Views
Cancer-News 5 days
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
Category: Other
6 Views
Cancer-News 5 days
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
25 Views
MD Anderson 5 days
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
Category: Other
12 Views
Cancer-News 5 days
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Category: News
8 Views
OSUCCC 5 days
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Category: Multiple Myeloma
12 Views
Cancer-News 5 days
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Category: News
17 Views
OSUCCC 6 days